Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
Yunkang Group Ltd
2325Yunkang Group Limited operates as a medical operation service provider in the People's Republic of China. The company offers diagnostic testing services for medical institution alliances, including setting up or upgrading diagnostic centers, the establishment of standard operating procedures for diagnostic testing, diagnostic consultation and staff training, procurement of equipment, smart internet of things, and logistics assistance. It also provides diagnostic outsourcing services comprising pathology tests; infectious disease diagnostic tests, including hepatitis B virus, tuberculosis, human papilloma virus, EB virus, rabies virus, and nucleic acid tests for respiratory pathogens; genetic reproduction, and screening tests. In addition, the company offers routine diagnostic tests for chronic kidney, blood, autoimmune, endocrine metabolism, and other diseases. Further, it provides diagnostic testing services for financial institutions and insurance companies, including personalized diagnostic testing, medical report consultation, and hospital referral services; information technology, medical logistics, and medical equipment procurement; and healthcare technology development. The company provides its services through independent clinical laboratories and on-site diagnostic centers. Yunkang Group Limited was founded in 2008 and is headquartered in Guangzhou, the People's Republic of China. Address: No. 9 Yayingshi Road, Guangzhou, China
Analytics
Zielpreis von Wall Street
102.13 HKDKGV
–Dividendenrendite
0.25 %Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Schlüsselzahlen 2325
Dividenden-Analyse 2325
Dividendenwachstum über 5 Jahre
–Kontinuierliches Wachstum
1 JahrAusschüttungsquote 5-Jahres-Durchschnitt
-53 %Verlauf der Dividende 2325
Bewertung der Aktie 2325
Finanzen 2325
Ergebnisse | 2019 | Dynamik |